| Tuberculosis and diabetes mellitus: convergence of two epidemics KE Dooley, RE Chaisson The Lancet infectious diseases 9 (12), 737-746, 2009 | 1267 | 2009 |
| The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis K Dheda, T Gumbo, G Maartens, KE Dooley, R McNerney, M Murray, ... The lancet Respiratory medicine 5 (4), 291-360, 2017 | 695 | 2017 |
| Tuberculous meningitis RJ Wilkinson, U Rohlwink, UK Misra, R Van Crevel, NTH Mai, KE Dooley, ... Nature reviews neurology 13 (10), 581-598, 2017 | 453 | 2017 |
| Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis KE Dooley, T Tang, JE Golub, SE Dorman, W Cronin The American journal of tropical medicine and hygiene 80 (4), 634, 2009 | 407 | 2009 |
| Four-month rifapentine regimens with or without moxifloxacin for tuberculosis SE Dorman, P Nahid, EV Kurbatova, PPJ Phillips, K Bryant, KE Dooley, ... New England Journal of Medicine 384 (18), 1705-1718, 2021 | 343 | 2021 |
| TMC207: the first compound of a new class of potent anti-tuberculosis drugs A Matteelli, ACC Carvalho, KE Dooley, A Kritski Future microbiology 5 (6), 849-858, 2010 | 245 | 2010 |
| Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study … KE Dooley, P Sayre, J Borland, E Purdy, S Chen, I Song, A Peppercorn, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 62 (1), 21-27, 2013 | 232 | 2013 |
| Risk factors for tuberculosis treatment failure, default, or relapse and outcomes of retreatment in Morocco KE Dooley, O Lahlou, I Ghali, J Knudsen, MD Elmessaoudi, I Cherkaoui, ... BMC public health 11, 1-7, 2011 | 231 | 2011 |
| Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis KE Dooley, J Golub, FS Goes, WG Merz, SR Timothy Clinical infectious diseases 34 (12), 1607-1612, 2002 | 177 | 2002 |
| Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine B Williamson, KE Dooley, Y Zhang, DJ Back, A Owen Antimicrobial agents and chemotherapy 57 (12), 6366-6369, 2013 | 147 | 2013 |
| Fluoroquinolone resistance in patients with newly diagnosed tuberculosis AS Ginsburg, N Hooper, N Parrish, KE Dooley, SE Dorman, J Booth, ... Clinical Infectious Diseases 37 (11), 1448-1452, 2003 | 136 | 2003 |
| World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? KE Dooley, EA Obuku, N Durakovic, V Belitsky, C Mitnick, ... The Journal of infectious diseases 207 (9), 1352-1358, 2013 | 133 | 2013 |
| GeneXpert MTB/Rif to diagnose tuberculous meningitis: perhaps the first test but not the last NC Bahr, S Marais, M Caws, R Van Crevel, RJ Wilkinson, JS Tyagi, ... Clinical Infectious Diseases 62 (9), 1133-1135, 2016 | 129 | 2016 |
| Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug EM Svensson, S Murray, MO Karlsson, KE Dooley Journal of Antimicrobial Chemotherapy 70 (4), 1106-1114, 2015 | 129 | 2015 |
| Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial SE Dorman, RM Savic, S Goldberg, JE Stout, N Schluger, G Muzanyi, ... American journal of respiratory and critical care medicine 191 (3), 333-343, 2015 | 126 | 2015 |
| Designing drug trials: considerations for pregnant women JS Sheffield, D Siegel, M Mirochnick, RP Heine, C Nguyen, KL Bergman, ... Clinical infectious diseases 59 (suppl_7), S437-S444, 2014 | 126 | 2014 |
| Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis EM Svensson, F Aweeka, JG Park, F Marzan, KE Dooley, MO Karlsson Antimicrobial agents and chemotherapy 57 (6), 2780-2787, 2013 | 120 | 2013 |
| The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis K Dheda, T Gumbo, G Maartens, KE Dooley, M Murray, J Furin, ... The Lancet Respiratory Medicine 7 (9), 820-826, 2019 | 117* | 2019 |
| Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries KE Dooley, F Charles, AS Andrade The Journal of infectious diseases 198 (7), 948-961, 2008 | 111 | 2008 |
| Importance of drug pharmacokinetics at the site of action ML Rizk, L Zou, RM Savic, KE Dooley Clinical and translational science 10 (3), 133, 2017 | 108 | 2017 |
Rada SavicProfessor, UCSFVerified email at ucsf.edu
